1. When Can a Drug or Medical Device Injury Support a Claim?
A serious side effect or complication does not by itself establish liability. A viable claim usually requires evidence connecting an actionable product defect or inadequate warning to the patient's injury, with the governing standards supplied primarily by applicable state law rather than the FDA regulatory scheme.
Product Defect and Warning Claims
Potential theories include defective manufacture, defective design, inadequate warnings, negligence, or breach of warranty, depending on the product and governing law. Product identification, prescribing history, warnings available at the relevant time, and the patient's medical course help determine which theory warrants investigation. The broader evidentiary framework is discussed in product liability lawsuit procedures.
Fatal Injuries
When an alleged product defect causes death, wrongful-death and survival claims raise separate questions about who may sue and which losses are recoverable. For claims governed by New York law, EPTL § 5-4.1 authorizes the decedent's personal representative to maintain the wrongful-death action and currently provides a two-year limitations period, subject to statutory qualifications. Related procedural issues are addressed in wrongful death litigation.
2. Fda Regulation and Product Liability Are Different Legal Frameworks
FDA regulation can shape the evidence and defenses in a life sciences case, but it does not replace state tort law. The FDCA generally places enforcement proceedings in the name of the United States, while patients ordinarily pursue available state-law causes of action; federal preemption may limit particular claims depending on the product, approval pathway, and duty alleged.
Regulatory Records Can Matter without Proving the Case
Labeling history, recalls, inspection materials, safety communications, and adverse-event reports can help establish a regulatory chronology. They do not automatically establish defect or causation. FDA states that the existence of an adverse-event report does not establish that the product caused the reported event and that such reports cannot be used alone to calculate incidence.
3. Medical Causation Often Controls Case Viability
A claimant must connect the drug or device to the injury while addressing underlying disease, other medications, prior conditions, dose or duration, implantation history, and other plausible causes. Medical records and expert analysis often determine whether that connection can be supported rather than merely assumed.
Evidence That Should Be Preserved
Useful evidence may include prescription and pharmacy records, operative reports, imaging, pathology, laboratory results, implant cards, packaging, lot or serial numbers, photographs, and communications with healthcare providers. An explanted device or remaining product can also become important physical evidence, so disposal or alteration may create avoidable proof problems.
4. Individual Claims and Multidistrict Litigation
When lawsuits involving the same product raise common factual questions in different federal districts, 28 U.S.C. § 1407 permits transfer for coordinated or consolidated pretrial proceedings. MDL does not itself convert individual personal-injury suits into a class action; each transferred action remains a separate case unless otherwise resolved. The scientific and expert-evidence issues that often arise in these disputes are discussed separately in life sciences litigation and expert gatekeeping.
5. Practical Pitfalls
Early assumptions can weaken an otherwise viable claim. A recall does not automatically establish liability, the absence of a recall does not necessarily defeat a claim, and an existing MDL does not automatically enroll every injured patient. Patients and families should also preserve product-identification and medical records and determine the applicable limitations period rather than assuming that a nationwide deadline exists.
New York Filing Periods Require Claim-Specific Review
For claims governed by New York law, CPLR 214 generally provides a three-year period for personal-injury actions, while CPLR 214-c contains a discovery-based rule for certain injuries caused by latent effects of exposure. Different rules can apply to wrongful death and other claims, so the date of injury alone may not answer the limitations question.
6. What Counsel Reviews in a Life Sciences Injury Matter
Counsel can identify the manufacturer and product, determine governing law and forum, review limitations issues, preserve evidence, obtain medical and regulatory records, assess defect and warning theories, analyze federal preemption, evaluate medical causation with appropriate experts, and address MDL procedure where relevant. Discovery, motion practice, damages analysis, negotiation, and trial preparation depend on what that initial factual and legal review shows.
7. Frequently Asked Questions
Patients and families often need to know whether FDA action, existing mass litigation, or the absence of a recall changes the viability of an individual claim.
Does an Fda Recall Prove Product Liability?
No. A recall may supply relevant evidence, but the claimant still must establish the elements required by the governing law, including causation.
Can a Claim Exist without an Fda Recall?
Yes, depending on the facts and governing law. FDA regulatory action and civil liability answer different legal questions.
Does an Existing Mdl Automatically Include My Claim?
No. A claim must be filed and, where appropriate, transferred or otherwise brought into the coordinated proceeding under the governing procedural rules.
8. Evaluating a Potential Life Sciences Injury Claim
A consultation can examine the product involved, medical chronology, applicable state law, FDA history, possible federal preemption, filing deadlines, available physical and documentary evidence, and any related MDL. That review helps determine which claims and procedural options merit further investigation.
28 Sep, 2026
